News

We are thrilled to announce that our CEO, Alain Parthoens Parthoens, was recently featured in an article by Nikkei Biotechnology & Business discussing the FDA Approval of Ogeda/Astellas' groundbreaking hot flash treatment.

The article, titled "アステラス期待のホットフラッシュ治療薬はこうして生まれた/The Birth of Astellas Pharma's Anticipated Hot Flash Treatment,” delves into the journey of this innovative drug, tracing its origins back to the leading investor of the former Ogeda in Belgium.

We extend our sincere gratitude to Mr Muneaki Hashimoto, the journalist from Nikkei Biotechnology & Business (the only portal site for the latest biotech news in Japan - according to them), for shedding light on this significant milestone. It is a testament to the dedication and hard work of our team that such recognition has been received.

We are excited about the positive impact this FDA approval will have on the lives of countless individuals experiencing hot flashes. At Newton Biocapital, we remain committed to driving innovation in the healthcare industry and improving patient outcomes.

Original Article in JP:
https://lnkd.in/efPbcia9

Google Translated Article in EN:
https://lnkd.in/eS8enEUZ